Massimo Leggio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Massimo Leggio has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
Andrea Mazza
Cardiology Division, Santa Maria della Stella Hospital, Orvieto, Italy
18 shared publicationsMaria Grazia Bendini
Cardiology Division, Santa Maria della Stella Hospital, Orvieto, Italy
15 shared publications- Augusto Fusco
UOSD High-Intensity Neurorehabilitation, Department of Neuroscience, Sensory Organs and Thorax, University Hospital Foundation “Agostino Gemelli” IRCCS, 00168 Rome, Italy
12 shared publications Massimo Armeni
Istituto di Alta Formazione, Rome, Italy
9 shared publicationsPaolo Severi
Department of Medicine and Rehabilitation, Cardiac Rehabilitation Operative Unit, San Filippo Neri Hospital-Salus Infirmorum Clinic, Rome, Italy; Physical Medicine and Neurorehabilitation Operative Unit, Salus Infirmorum Clinic, Rome, Italy
9 shared publicationsElisa Caldarone
Physical Medicine and Neurorehabilitation Operative Unit, Salus Infirmorum Clinic, Rome, Italy
8 shared publications
Latest Publications
- Open Access
- 3 August 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (8) , 2487
Cardiac Rehabilitation and Endothelial Function
Endothelial dysfunction is an early abnormality in the process of atherosclerosis and cardiovascular disease and has been associated with worse clinical outcome. Cardiac rehabilitation (CR) has been reported to be helpful to reduce cardiovascular events in various types of cardiac disease, but the mechanisms of its beneficial effects remain only partially known. In this article, we review the studies that assessed the effect of CR on endothelial function in patients with various cardiac conditions. Available data show that CR significantly improves impaired endothelial function in these patients, which may contribute to the beneficial effects of CR on clinical outcome.
- 3 August 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (8) , 2487
Open AccessCardiac Rehabilitation and Endothelial Function
Endothelial dysfunction is an early abnormality in the process of atherosclerosis and cardiovascular disease and has been associated with worse clinical outcome. Cardiac rehabilitation (CR) has been reported to be helpful to reduce cardiovascular events in various types of cardiac disease, but the mechanisms of its beneficial effects remain only partially known. In this article, we review the studies that assessed the effect of CR on endothelial function in patients with various cardiac conditions. Available data show that CR significantly improves impaired endothelial function in these patients, which may contribute to the beneficial effects of CR on clinical outcome.
- 1 August 2019
- Published by Elsevier in The American Journal of Medicine
- Vol. 132 (8) , e669-E669
The Effects of Dairy Consumption on Blood Pressure and Risk of Hypertension
- 1 August 2019
- Published by Elsevier in The American Journal of Medicine
- Vol. 132 (8) , e669-E669
The Effects of Dairy Consumption on Blood Pressure and Risk of Hypertension
- Open Access
- 9 May 2019
- Published by Wiley in Journal of Internal Medicine
- Vol. 286 (3) , 358-360
Smartphone‐based clinical diagnostics and atrial fibrillation: the need to avoid being out of sight
- 9 May 2019
- Published by Wiley in Journal of Internal Medicine
- Vol. 286 (3) , 358-360
Open AccessSmartphone‐based clinical diagnostics and atrial fibrillation: the need to avoid being out of sight
- 1 May 2019
- Published by Elsevier in The American Journal of Medicine
- Vol. 132 (5) , e564-E564
Cardiorespiratory Fitness in Healthy People: A Step Forward to Primary Cardiovascular Health Promotion
- 1 May 2019
- Published by Elsevier in The American Journal of Medicine
- Vol. 132 (5) , e564-E564
Cardiorespiratory Fitness in Healthy People: A Step Forward to Primary Cardiovascular Health Promotion
- Open Access
- 11 April 2019
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 26 (16) , 1781-1782
A precision medicine approach for the primary prevention of cardiovascular events in diabetic patients
- 11 April 2019
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 26 (16) , 1781-1782
Open AccessA precision medicine approach for the primary prevention of cardiovascular events in diabetic patients
- Open Access
- 8 April 2019
- Published by Wiley in Journal of Internal Medicine
- Vol. 286 (1) , 112-114
Precision medicine for diabetes management and primary cardiovascular prevention
- 8 April 2019
- Published by Wiley in Journal of Internal Medicine
- Vol. 286 (1) , 112-114
Open AccessPrecision medicine for diabetes management and primary cardiovascular prevention
- Open Access
- 18 November 2018
- Published by Wiley in Journal of Internal Medicine
- Vol. 285 (4) , 469-471
Anti‐inflammatory diet to reduce mortality: is it time for a precision medicine approach?
- 18 November 2018
- Published by Wiley in Journal of Internal Medicine
- Vol. 285 (4) , 469-471
Open AccessAnti‐inflammatory diet to reduce mortality: is it time for a precision medicine approach?
- 1 October 2018
- Published by Elsevier in The American Journal of Medicine
- Vol. 131 (10) , e425-E425
Exercise Training in Obese Patients with Heart Failure: Time to Tackle the Burden
- 1 October 2018
- Published by Elsevier in The American Journal of Medicine
- Vol. 131 (10) , e425-E425
Exercise Training in Obese Patients with Heart Failure: Time to Tackle the Burden
- 1 September 2018
- Published by Elsevier in The American Journal of Medicine
- Vol. 131 (9) , e387-E387
The Role of Physical Activity in the New 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines
- 1 September 2018
- Published by Elsevier in The American Journal of Medicine
- Vol. 131 (9) , e387-E387
The Role of Physical Activity in the New 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines
- 21 August 2018
- Published by Springer Nature in Drugs
- Vol. 78 (13) , 1309-1319
Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation: The Triple Trouble
One of the most common conundrums in all cardiovascular medicine pertains to the care of patients with atrial fibrillation after percutaneous coronary intervention, because of both dual antiplatelet therapy and oral anticoagulant therapy would seem to be necessary to reduce risks of stent thrombosis and thromboembolism, respectively, but also with an inevitable trade-off of more bleeding. Patients who require triple therapy are at high risk of both ischaemia and bleeding; therefore, defining a personalised secondary prevention strategy aimed at achieving the best net clinical benefit is essential. The good news is that we have entered an era of increased perceived and tangible safety that applies to both non-vitamin K-antagonist oral anticoagulants and newer drug-eluting stents. Even if the consistency across the major trials and the significantly lower risk of bleeding with dual therapy make it hard to argue that triple therapy should be used routinely, the aggregate evidence suggests that the net clinical benefit of dual therapy should give cardiologists confidence to drop aspirin when they are using a contemporary percutaneous coronary intervention strategy with drug-eluting stents. Waiting for more randomised trials and meta-analyses, for the time being, in patients not in clinical trials, full-dose oral triple therapy with dual antiplatelet agents and full-dose anticoagulation should be avoided as a routine practice, and the choice of the proper, that is, safer, oral anticoagulant, namely a non-vitamin K-antagonist oral anticoagulant, may be regarded by now as an additional bleeding avoiding strategy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
- 21 August 2018
- Published by Springer Nature in Drugs
- Vol. 78 (13) , 1309-1319
Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation: The Triple Trouble
One of the most common conundrums in all cardiovascular medicine pertains to the care of patients with atrial fibrillation after percutaneous coronary intervention, because of both dual antiplatelet therapy and oral anticoagulant therapy would seem to be necessary to reduce risks of stent thrombosis and thromboembolism, respectively, but also with an inevitable trade-off of more bleeding. Patients who require triple therapy are at high risk of both ischaemia and bleeding; therefore, defining a personalised secondary prevention strategy aimed at achieving the best net clinical benefit is essential. The good news is that we have entered an era of increased perceived and tangible safety that applies to both non-vitamin K-antagonist oral anticoagulants and newer drug-eluting stents. Even if the consistency across the major trials and the significantly lower risk of bleeding with dual therapy make it hard to argue that triple therapy should be used routinely, the aggregate evidence suggests that the net clinical benefit of dual therapy should give cardiologists confidence to drop aspirin when they are using a contemporary percutaneous coronary intervention strategy with drug-eluting stents. Waiting for more randomised trials and meta-analyses, for the time being, in patients not in clinical trials, full-dose oral triple therapy with dual antiplatelet agents and full-dose anticoagulation should be avoided as a routine practice, and the choice of the proper, that is, safer, oral anticoagulant, namely a non-vitamin K-antagonist oral anticoagulant, may be regarded by now as an additional bleeding avoiding strategy in patients with atrial fibrillation undergoing percutaneous coronary intervention.